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Abstract—The quaternary ?-carbolinium alkaloid nostocarboline from the cyanobacterium Nostoc 78-12A and ten bis-cationic dimeric 
derivatives were evaluated against four protozoan parasites and low micromolar values against Trypanosoma brucei, submicromolar 
values against Leishmania donovani and low nanomolar values against Plasmodium falciparum K1 were determined. Selectivity against 
rat myoblasts (L6 cells) was found to be up to > 2500 fold. ©2008 Elsevier Science Ltd. All rights reserved. 
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Malaria remains a public health problem in large areas 
of the developing world, with 40% of the earth’s 
population living in malaria-endangered areas.
1
 As a 
direct consequence, over 1 million humans die annually 
of this disease, with the number of clinical cases 
estimated to be a hundred times higher.
2
 These public 
health problems are accentuated by the rise of malaria 
cases in yet non-endemic areas, and increasing 
resistance of Plasmodium to current lines of therapy.
3
 
These facts combined with the absence of a vaccine and 
the lack of systematic vector control strategies provides 
the rationale for the development of novel drugs against 
this disease.
4
 
 
Natural products are extremely successful in providing 
mankind with substances to combat diseases, and today, 
roughly 50% of all small molecule drugs on the market 
addressing infectious diseases are natural products or 
derivatives thereof.
5
 With respect to malaria, quinine 
and its derivatives are still in use today, and new 
therapies based on artemisinin were recently introduced 
in the clinic.
4
 Cyanobacteria have been shown to be an 
important source for novel bioactive natural products, as 
these organisms face large pressure from grazers or 
competing organisms requiring them to develop 
chemical defense strategies.
6
 Several cyanobacterial 
metabolites have been shown to possess antiplasmodial 
activity: Calothrixins A and B inhibited the FAF6 strain 
of Plasmodium falciparum with IC50 values of roughly 
60 and 180 nM, albeit with no or very little selectivity 
against HeLa human tumor cell lines.
7a
 Venturamide B 
displayed a low micromolar value against Plasmodium 
falciparum W2 with a selectivity > 10 against green 
monkey Vero kidney cells reported.
7b
 Symplocamide A 
displayed an IC50 value of 0.95 ?M against the same 
strain, but rather strong cytotoxicity.
7c
 We have recently 
isolated nostocarboline (1), an acetyl- and butyryl-
cholinesterase, and trypsin inhibitor from Nostoc 78-
12A.
8
 Moreover, this compound class has been shown 
to possess strong algicidal activity against both 
eukaryotic and prokaryotic phototrophs.
9
 The chemical 
ecology rationale for evaluating nostocarboline against 
Plasmodium was based on a large body of research 
demonstrating that Plasmodium contains a plastid-like 
organelle, which was suggested to be a relic of a 
photoautotrophic (cyanobacterial) endosymbiont.
10
 
Targeting this apicoplast with algicidal compounds has 
been suggested as a strategy for effective antiplasmodial 
  
agents.
11
 In this communication, we demonstrate that 
nostocarboline (1) inhibits Plasmodium with high 
selectivity in nanomolar concentrations. In addition, we 
demonstrate that dimerization of nostocarboline leads to 
very potent and selective antiplasmodial agents. This 
latter route presents a strategic option for the chemical 
diversification of natural products
12
 and provides an 
entry into bis-cationic compounds, a class of 
compounds known for strong antiplasmodial activity.
13 
 
Nostocarboline (1) was synthesized according to 
published procedures starting from norharmane via 
chlorination at C-6 and methylation (Scheme 1).
8a
 6-Cl-
norharmane was also the starting material for the 
synthesis of nostocarboline homo-dimers, which were 
prepared using symmetrical dihalogeno-linkers to afford 
the desired bis-?-carbolinium homo-dimers 2-11 (Table 
1). We were able to employ alkenyl, alkynyl, aryl and 
biaryl, as well as alkyl linkers of various lengths for the 
corresponding dimers, which were obtained in a two-
step process and isolated in good to excellent yields. It 
should be pointed out that cheap, short and high-
yielding syntheses should be regarded as a requirement 
for successful antimalarial agents, given the prevalence 
of this disease in developing countries. 
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Scheme 1. Reagents and conditions: (a) NaOCl, EtOH, 0 °C, 30 min, then 
r.t., 5 h, 75%; b) CH3I, i-PrOH, reflux, 4 h, 94%; c) dihalogeno-linkers, i-
PrOH, reflux, 12-48 h, 60-95%. 
 
Nostocarboline (1) as well as its dimers 2-11 were 
evaluated against four parasites, Trypanosoma brucei 
rhodesiense STIB 900, Trypanosoma cruzi Tulahuen 
C2C4, Leishmania donovani MHOM-ET-67/L82 axenic 
amastigotes, and Plasmodium falciparum K1 and the 
corresponding IC50 values are given in Table 2. 
Nostocarboline (1) showed a pronounced activity 
against Plasmodium (IC50 = 194 nM), while being 
inactive against the other parasites tested. In addition, 
nostocarboline (1) showed very weak cytotoxicity (> 
0.1 mM), giving rise to a 600 fold selectivity of 
Plasmodium over L6 cells. The results for the dimers 2-
11 display a consistent pattern of activity: While against 
T. brucei IC50 values around 1 ?M were determined, the 
dimers 2-11 were roughly by a factor of 5 to 50 less 
active against T. cruzi. Interesting submicromolar 
activity against L. donovani could be determined for 
some dimers, in particular those incorporating a long, 
flexible linker such as 7-11. In this series, higher 
activity nicely correlates with longer linkers. 
Interestingly, the most active compound was the dimer 
5 with the meta substituted aryl linker (0.2 ?M), which 
was roughly 100 fold more active than dimer 4 with the 
corresponding para substituted linker. This suggests 
that relative orientation of the two nostocarboline units 
has an impact on activity against L. donovani. 
 
Table 1. Structure of bis-?-carbolinium homodimers 2-11.  
 
Compounda Linker Time (h) Yield (%) 
2 
 
12 72 
3 
 
12 65 
4 12 95 
5 
 
12 89 
6 
 
12 86 
7 O  24 60 
8  48 93 
9  48 87 
10  48 78 
11  48 71 
a For 2-7: X=Cl; for 8-11: X=Br. 
 
The best results were obtained against Plasmodium 
falciparum, where submicromolar IC50 values were 
determined for all dimers 2-11. In this series and against 
this parasite, long and flexible linkers are preferred, 
with the corresponding compounds 6-11 all displaying 
IC50 values below 100 nM. The most active compound 
10 containing a (CH2)10 linker displayed an IC50 value 
of 14 nM against P. falciparum K1. 
 
We also determined cytotoxicity against the L6 rat 
myoblast cell line, and the values were generally 
dispersed in the 5-60 ?M range. While the effect of 
linker length on antiplasmodial activity residues for 7-
11 was very small, its effect on cytotoxicity was more 
pronounced. Clearly, cytotoxicity increased with linker 
length, thus leading to decreased selectivity for longer 
linkers. Compounds 7 and 8 with 5 and 6 atom linkers 
can thus be considered optimal in this series, as e.g. 7 
displayed high potency (18 nM) and an excellent 
selectivity of > 2500 fold against the L6 cell line. 
These results complement the interesting biological 
profile of nostocarboline: While this compound strongly 
  
inhibits the growth of cyanobacteria and eukaryotic 
chlorophytes,
9
 it is inactive against bacterial pathogens 
and fungi,
9
 and very weakly toxic against mammalian 
eukaryotic cells (Table 2) and crustaceans.
8b
 At the 
same time, activity against Plasmodium was observed. 
It is tempting to speculate that this activity might be 
correlated with the presence of plastids of 
cyanobacterial origin in Plasmodium, where the actual 
targets of nostocarboline might be present. Whether 
these targets are related to the known inhibitory action 
of nostocarboline on hydrolytic enzymes such as 
esterases and proteases must be validated. It is also 
unclear at present, whether nostocarboline and its 
dimers 2-11 act via the same mode of action on 
Plasmodium: The increased cytotoxicity (and decreased 
selectivity) of some of the dimers suggests a competing 
non-selective pathway for some dimers (e.g. 4 and 5).  
 
Table 2. Antiparasitic in vitro activities of 1-12 (values in ?M). 
 
 
T. b.a 
IC50 
T. c.b 
IC50 
L. d.c 
IC50 
P. f.d 
IC50 
Cytotoxicitye 
IC50 
Selectivity 
P. f.f 
1 70.5 > 87.1 34.3 0.194 120.9 622 
2 1.1 > 56.6 9.6 0.113 61.1 540 
3 6.4 10.6 34.7 0.738 28.5 39 
4 1 > 51.7 19.9 0.223 17.4 78 
5 1.2 5.9 0.2 0.121 3.8 32 
6 2.5 > 45.7 68.4 0.056 23 408 
7 1.2 51.1 8.6 0.018 47.9 2625 
8 1.2 36.2 6.6 0.020 36.2 1810 
9 0.9 31.4 2.3 0.018 7.5 423 
10 1.1 36.6 0.9 0.014 8.2 575 
11 1.2 10 0.6 0.023 4.3 186 
12 92.5 > 44.6 61.6 > 7.4 121.3 n.d.g 
a Trypanosoma brucei rhodesiense STIB 900 
b Trypanosoma cruzi Tulahuen C2C4 
c Leishmania donovani MHOM-ET-67/L82 
d Plasmodium falciparum K1 
e Rat myoblast L6 cells  
f The selectivity index is calculated by IC50(L6)/IC50(P.f.) 
g n.d.: not determined 
 
An interesting compound to evaluate the mode of 
action, as well as potential resistance mechanisms, is the 
hybrid 12 of nostocarboline and ciprofloxacin (Figure 
1).
9
 Such dual mode of action hybrids combine the 
distinct bioactivity of two different fragments leading to 
synergistic mode of action.
14
 We have shown that 12 
retains the activity of nostocarboline, with increased 
properties against some bacteria.
9
 Interestingly, against 
the parasites evaluated, compound 12 was found to be 
inactive (Table 2). 
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Figure 1. Structure of the quinolone ?-carbolinium hybrid 12. 
 
The results obtained in this study also favorably 
compare to other carbolinium natural products with 
antiplasmodial activity, such as e.g. normelinonine F,
15a
 
fascaplysin,
15b
 and cryptolepine
15a,15c
. While the 
activities of these natural products against Plasmodium 
falciparum are comparable, higher selectivity was 
observed for nostocarboline (1). The tetra- and penta-
cyclic framework of cryptolepine and fascaplysine 
appear to increase DNA intercalation properties 
resulting in increased unspecific cell toxicity
15
. In 
addition, while natural dimeric cryptolepine alkaloids 
were inactive against Plasmodium,
15c
 synthetic 
nostocarboline dimers such as 7 resulted in significantly 
higher activity.  
In conclusion we have shown that nostocarboline (1) 
and its symetrical homodimers 2-11 are potent and 
selective inhibitors of Plasmodium falciparum and 
display also interesting activity against Leishmania 
donovani. The compound with the best profile was 
dimer 7, with an IC50 against Plasmodium falciparum of 
18 nM and a > 2500 fold selectivity against L6 cells. 
The benefits of the presented compounds thus include 
(1) ease of synthesis in two steps from norharmane; (2) 
potent activity down to 14 nM against Plasmodium 
falciparum and (3) weak cytotoxicity resulting in 
selectivities of up to > 2500 fold. The elucidation of the 
mode of action as well as evaluation in animal models is 
now being carried out in our laboratories. 
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